Randomized phase II trial of sulindac for lung cancer chemoprevention
โ Scribed by Limburg, Paul J.; Mandrekar, Sumithra J.; Aubry, Marie Christine; Ziegler, Katie L. Allen; Zhang, Jun; Yi, Joanne E.; Henry, Michael; Tazelaar, Henry D.; Lam, Stephen; McWilliams, Annette; Midthun, David E.; Edell, Eric S.; Rickman, Otis B.; Mazzone, Peter; Tockman, Melvyn; Beamis, John F.; Lamb, Carla; Simoff, Michael; Loprinzi, Charles; Szabo, Eva; Jett, James
- Book ID
- 122804270
- Publisher
- Elsevier Science
- Year
- 2013
- Tongue
- English
- Weight
- 562 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Well-designed and conducted Phase 11 clinical trials are very important to cancer chemoprevention drug development. Three critical aspects govern the design and conduct of these trials-wellcharacterized agents, suitable cohorts, and reliable biomarkers for measuring efficacy that can serve as surrog